title: Evidence for the efficacy of an 8% strontium acetate dentifrice for instant and lasting relief of dentin hypersensitivity.
abstract: An 8% strontium acetate, 1040 ppm sodium fluoride-based dentifrice has been demonstrated in in vitro and in situ studies to provide deep and acid-resistant tubule occlusion. Clinical efficacy studies have shown instant and lasting dentin hypersensitivity relief from this dentifrice, which has recently been launched by GlaxoSmithKline Consumer Healthcare as Sensodyne Rapid Relief.
authors.affiliation: GlaxoSmithKline Consumer Healthcare, Weybridge, Surrey, UK. teresa.m.layer@gsk.com
authors.forename: Teresa
authors.initials: T
authors.lastname: Layer
authors.forename: Nathan
authors.initials: N
authors.lastname: Hughes
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D003802:Dentifrices / Q000008:administration & dosage / Q000627:therapeutic use*; D003804:Dentin / Q000187:drug effects / Q000648:ultrastructure; D057133:Dentin Desensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003807:Dentin Sensitivity / Q000517:prevention & control*; D006801:Humans; D008422:Materials Testing; D016032:Randomized Controlled Trials as Topic; D012969:Sodium Fluoride / Q000008:administration & dosage / Q000627:therapeutic use; D013324:Strontium / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000085:Acetates; D003802:Dentifrices; D057133:Dentin Desensitizing Agents; C106741:strontium acetate; D012969:Sodium Fluoride; D013324:Strontium